US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nuo Therapeutics, Inc.

1.30

0.0000

Volume:- -

Turnover:- -

Market Cap:62.96M

PE:-31.06

High:1.30

Open:1.30

Low:1.30

Close:1.30

52wk High:2.92

52wk Low:0.7700

Shares:48.43M

Float Shares:23.46M

Volume Ratio:1.18

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0419

EPS(LYR):-0.0293

ROE:-1032.50%

ROA:-54.33%

PB:-41.01

PE(LYR):-44.44

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Nuo Therapeutics Closes $325,000 Loan Funding Under Amended Lending Agreement

Press Release: Nuo Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Nuo Therapeutics Q2 FY26 Revenue More than Doubles to $1.77 Million; Gross Profit Climbs to $1.17 Million

Nuo Therapeutics amends loan deal, lifts lender commitments to USD 2 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/AURX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AURX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AURX\",,,,,undefined,":{"symbol":"AURX","market":"US","secType":"STK","nameCN":"Nuo Therapeutics, Inc.","latestPrice":1.3,"timestamp":1793217600000,"preClose":1.3,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":23458700,"shares":48433800,"eps":-0.041859,"marketStatus":"Pre-Mkt","change":0,"latestTime":"10-28 16:00:00 EDT Delay","open":1.3,"high":1.3,"low":1.3,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.041859,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1793280600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":1.3,"volumeRatio":1.1801224754758062},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AURX\",,,,,undefined,":{"symbol":"AURX","floatShares":23458700,"roa":"-54.33%","roe":"-1032.50%","lyrEps":-0.029253,"volumeRatio":1.1801224754758062,"shares":48433800,"dividePrice":0,"high":1.3,"amplitude":0,"preClose":1.3,"low":1.3,"week52Low":0.77,"pbRate":"-41.01","psRate":"12.11","week52High":2.92,"institutionHeld":0,"latestPrice":1.3,"eps":-0.041859,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.041859,"open":1.3,"prevYearClose":1.97,"prevWeekClose":1.3,"prevMonthClose":1.25,"prevQuarterClose":1.25,"fiveDayClose":1.3,"twentyDayClose":1.25,"sixtyDayClose":1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AURX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-08-12","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1723435200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-19","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1713499200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-20","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1700456400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AURX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AURX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AURX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673924065","title":"Nuo Therapeutics Closes $325,000 Loan Funding Under Amended Lending Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2673924065","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673924065?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:58","pubTimestamp":1791320295,"startTime":"0","endTime":"0","summary":"Nuo Therapeutics closes $325,000 loan funding under amended lending agreementNuo Therapeutics amended its May 29, 2026 Amended and Restated Loan and Security Agreement to reset the $325,000 Second Fun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL3fxZZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660487499","title":"Press Release: Nuo Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487499","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660487499?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:20","pubTimestamp":1786969200,"startTime":"0","endTime":"0","summary":"Differentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term GrowthHOUSTON, Aug. 17, 2026  -- Nuo Therapeutics, Inc.  , a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the second quarter ended June 30, 2026 and provided an operational and business update.Second Quarter and First Half 2026 Financial Summary-- Total revenues of approximately $1.77 million and $3.07 million for the. second quarter 2026 and first half of 2026, respectively, were each up in. -- Total 2Q product revenues increased 38% sequentially versus 1Q 2026 with. Aurix branded product revenues increasing in excess of 30% sequentially. -- Second quarter net operating loss of approximately $167,000 improved by. approximately $280,000 compared to the first quarter of 2026. -- Amended and restated loan agreement with an interim funding of $675,000. and with $325,000 remaining available under commitm","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURX","BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659312483","title":"Nuo Therapeutics Q2 FY26 Revenue More than Doubles to $1.77 Million; Gross Profit Climbs to $1.17 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659312483","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659312483?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:18","pubTimestamp":1786742319,"startTime":"0","endTime":"0","summary":"Nuo Therapeutics Q2 FY26 revenue more than doubles to $1.77 million; gross profit climbs to $1.17 millionNuo Therapeutics posted Q2 revenue of USD 1.77 million, more than doubled from a year earlier, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL48ZRND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640591903","title":"Nuo Therapeutics amends loan deal, lifts lender commitments to USD 2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2640591903","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640591903?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:01","pubTimestamp":1780480908,"startTime":"0","endTime":"0","summary":"Nuo Therapeutics amended and restated its loan and security agreement with five lenders on May 29, lifting total commitments to USD 2 million.USD 1 million funded in January, USD 675,000 funded May 29, USD 325,000 available Sept. 30 subject to conditions.Notes carry 12% annual interest, payable in Interest Warrants rather than cash; maturity remains Dec. 31, 2028.Debt is secured by a lien on all company assets, including intellectual property; proceeds earmarked for working capital.Deal includes warrants at USD 1.5 per share; mandatory prepayment triggered by a USD 5 million equity raise or a change in control.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuo Therapeutics Inc. published the original content used to generate this news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL7KwpMr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AURX\",params:#limit:6,delay:false,,,undefined,":[]}}